Urmărește feeduri: bloguri, știri, RSS și altele. Un mod simplu de a citi și de a parcurge conținutul ales de tine.
Obține FeederFluxurile RSS despre Oncologie cele mai urmărite de utilizatorii Feeder, inclusiv Frontiers in Oncology | New and Recent Articles, ScienceDirect Publication: Nuclear Medicine and Biology și JNCI: Journal of the National Cancer Institute Advance Access. Copiază adresa URL a unui flux sau urmărește-le gratuit în Feeder.
Feeduri RSS Sănătate Feeduri RSS Studii clinice Feeduri RSS Cercetare medicală Feeduri RSS Sănătate mintală Feeduri RSS Psihologie Feeduri RSS Sănătate publică Feeduri RSS Industria farmaceutică
Sugerează o modificareRSS Feed for Frontiers in Oncology | New and Recent Articles
ScienceDirect RSS
This feed contains articles for bioRxiv Subject Collection "Cancer Biology"
Business Wire - The global leader in news distribution
Please follow the links to view the content.
<em>Cancer Gene Therapy</em> is the essential gene and cellular therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene and cellular therapies for cancer. Publication topics include RNAi approaches, drug resistance, hematopoietic progenitor cell gene transfer, cancer stem cells, cellular therapies, homologous recombination, ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy (antisense, siRNA & ribozymes), apoptosis; mechanisms and therapies, vaccine development, immunology and immunotherapy, DNA synthesis and repair. <em>Cancer Gene Therapy</em> publishes the results of laboratory investigations, preclinical studies, and clinical trials in the field of gene transfer/gene therapy and cellular therapies as applied to cancer research. Articles published include the fields of drug resist
investors.bicycletherapeutics.com
The Investor Relations website contains information about Bicycle Therapeutics's business for stockholders, potential investors, and financial analysts.